Literature DB >> 25806151

Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Gerald W Prager1, Marina Poettler1, Matthias Unseld1, Christoph C Zielinski1.   

Abstract

It is now widely accepted that tumor-angiogenesis plays a crucial role in tumor growth, tumor propagation and metastasis formation. Among several angiogenic activators, the vascular endothelial growth factor (VEGF) and its receptors represent one of the major inducers of tumor angiogenesis. Thus, this system has become the focus of therapeutic interventions, which led to the approval of the anti-VEGF blocking antibody bevacizumab and the VEGFR-2 pathway inhibitors pazopanib, sorafenib and sunitinib. However, not every cancer patient benefits from such treatment or finally becomes resistant to anti-VEGF approaches; others are suffering from adverse effects. Thus, there is an urgent need for a better understanding of VEGF-independent mechanisms leading to angiogenesis in cancer. This review focuses on anti-VEGF escape mechanisms of tumor cells and its microenvironment.

Entities:  

Keywords:  VEGF; angiogenesis; cancer; endothelial cells

Year:  2012        PMID: 25806151      PMCID: PMC4367591          DOI: 10.3978/j.issn.2218-6751.2011.11.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  140 in total

1.  LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation.

Authors:  J Herz; D E Clouthier; R E Hammer
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

2.  The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis.

Authors:  Donald R Senger; Carole A Perruzzi; Michael Streit; Victor E Koteliansky; Antonin R de Fougerolles; Michael Detmar
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Authors:  Tina Cascone; Matthew H Herynk; Li Xu; Zhiqiang Du; Humam Kadara; Monique B Nilsson; Carol J Oborn; Yun-Yong Park; Baruch Erez; Jörg J Jacoby; Ju-Seog Lee; Heather Y Lin; Fortunato Ciardiello; Roy S Herbst; Robert R Langley; John V Heymach
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

4.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

5.  Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.

Authors:  Alejandro D Ricart; Anthony W Tolcher; Glenn Liu; Kyle Holen; Garry Schwartz; Mark Albertini; Geoffrey Weiss; Salim Yazji; Chee Ng; George Wilding
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

6.  Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.

Authors:  Sung Yong Oh; Won Seog Kim; Dae Ho Lee; Seok Jin Kim; Sung Hyun Kim; Baek Yeol Ryoo; Hye Jin Kang; Young Jin Choi; Joo Seop Chung; Hyo Jung Kim; Cheolwon Suh
Journal:  Invest New Drugs       Date:  2009-05-07       Impact factor: 3.850

7.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

Review 8.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Authors:  Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

9.  Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.

Authors:  J B Vermorken; J Guigay; R Mesia; J M Trigo; U Keilholz; A Kerber; U Bethe; M Picard; T H Brummendorf
Journal:  Br J Cancer       Date:  2011-05-03       Impact factor: 7.640

10.  Embryonic mesodermal defects in alpha 5 integrin-deficient mice.

Authors:  J T Yang; H Rayburn; R O Hynes
Journal:  Development       Date:  1993-12       Impact factor: 6.868

View more
  35 in total

1.  Effects of SASH1 on lung cancer cell proliferation, apoptosis, and invasion in vitro.

Authors:  En-guo Chen; Yanfan Chen; Liang-liang Dong; Ji-song Zhang
Journal:  Tumour Biol       Date:  2012-04-10

2.  A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.

Authors:  Jin-Cherng Lien; Chi-Li Chung; Tur-Fu Huang; Tsung-Chia Chang; Kuan-Chung Chen; Ging-Yan Gao; Ming-Jen Hsu; Shiu-Wen Huang
Journal:  Br J Pharmacol       Date:  2019-09-15       Impact factor: 8.739

Review 3.  Therapies targeting cancer stem cells: Current trends and future challenges.

Authors:  Denisa L Dragu; Laura G Necula; Coralia Bleotu; Carmen C Diaconu; Mihaela Chivu-Economescu
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

4.  The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model.

Authors:  Chunfang Hao; Yehui Shi; Jinpu Yu; Xueqing Wei; Shufen Li; Zhongsheng Tong
Journal:  Mol Cell Biochem       Date:  2012-05-01       Impact factor: 3.396

5.  Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.

Authors:  Liu Yang; Mei Liu; Chuanzong Deng; Zhikai Gu; Yilu Gao
Journal:  Tumour Biol       Date:  2012-04-29

Review 6.  Stromal contributions to the carcinogenic process.

Authors:  Mark Spaw; Shrikant Anant; Sufi Mary Thomas
Journal:  Mol Carcinog       Date:  2016-11-05       Impact factor: 4.784

Review 7.  Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.

Authors:  Anoop K Yadav; Neetin S Desai
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

8.  An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer.

Authors:  Aleksei Viktorovich Novik; Anna Borisovna Danilova; Maksim Ivanovich Sluzhev; Tatiana Leonidovna Nehaeva; Sergei Sergeevich Larin; Dmitry Viktorovich Girdyuk; Svetlana Anatolevna Protsenko; Anna Igorevna Semenova; Aleksei Olegovich Danilov; Vladimir Mikhailovich Moiseyenko; Georgii Pavlovich Georgiev; Irina Aleksandrovna Baldueva
Journal:  Oncologist       Date:  2020-04-07

9.  Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.

Authors:  Xiaohong Wu; Li Liang; Liangliang Dong; Zhe Yu; Xiaoqing Fu
Journal:  Mol Biol Rep       Date:  2012-12-18       Impact factor: 2.316

10.  Involvement of ZEB1 and E-cadherin in the invasion of lung squamous cell carcinoma.

Authors:  Jiaxing Zhang; Chenhui Lu; Jun Zhang; Jiuhong Kang; Chuanwu Cao; Maoquan Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.